Ashley M Lucke1,2, Anil N Shetty3, Joseph L Hagan4, Allison Walton4, Tiffany D Stafford4, Zili D Chu5, Christopher J Rhee4, Jeffrey R Kaiser6, Magdalena Sanz Cortes3. 1. Fetal Medicine Institute, Children's National Health System, 111 Michigan Ave. NW, Washington, DC, 20010, USA. AshleyLuckeMD@gmail.com. 2. Department of Pediatrics (Neonatology), Baylor College of Medicine, Houston, TX, USA. AshleyLuckeMD@gmail.com. 3. Department of Obstetrics and Gynecology, Baylor College of Medicine, Texas Children's Hospital Pavilion for Women, Houston, TX, USA. 4. Department of Pediatrics (Neonatology), Baylor College of Medicine, Houston, TX, USA. 5. Department of Radiology, Baylor College of Medicine, Houston, TX, USA. 6. Departments of Pediatrics (Neonatal-Perinatal Medicine) and Obstetrics and Gynecology, Penn State Health Children's Hospital, Hershey, PA, USA.
Abstract
BACKGROUND: Hypoxic-ischemic encephalopathy (HIE) remains a significant cause of mortality and neurodevelopmental impairment despite treatment with therapeutic hypothermia. Magnetic resonance H1-spectroscopy measures concentrations of cerebral metabolites to detect derangements in aerobic metabolism. OBJECTIVE: We assessed MR spectroscopy in neonates with HIE within 18-24 h of initiating therapeutic hypothermia and at 5-6 days post therapeutic hypothermia. MATERIALS AND METHODS: Eleven neonates with HIE underwent MR spectroscopy of the basal ganglia and white matter. We compared metabolite concentrations during therapeutic hypothermia and post-therapeutic hypothermia and between moderate and severe HIE. RESULTS: During therapeutic hypothermia, neonates with severe HIE had decreased basal ganglia N-acetylaspartate (NAA; 0.62±0.08 vs. 0.72±0.05; P=0.02), NAA + N-acetylaspartylglutamate (NAAG; 0.66±0.11 vs. 0.77±0.06; P=0.05), glycerophosphorylcholine + phosphatidylcholine (GPC+PCh; 0.28±0.05 vs. 0.38±0.06; P=0.02) and decreased white matter GPC+PCh (0.35±0.13 vs. 0.48±0.04; P=0.02) compared to neonates with moderate HIE. For all subjects, basal ganglia NAA decreased (-0.08±0.07; P=0.01), whereas white matter GPC+PCh increased (0.03±0.04; P=0.04) from therapeutic hypothermia MRI to post-therapeutic-hypothermia MRI. All metabolite values are expressed in mmol/L. CONCLUSION: Decreased NAA and GPC+PCh were associated with greater HIE severity and could distinguish neonates who might benefit most from targeted additional neuroprotective therapies.
BACKGROUND:Hypoxic-ischemic encephalopathy (HIE) remains a significant cause of mortality and neurodevelopmental impairment despite treatment with therapeutic hypothermia. Magnetic resonance H1-spectroscopy measures concentrations of cerebral metabolites to detect derangements in aerobic metabolism. OBJECTIVE: We assessed MR spectroscopy in neonates with HIE within 18-24 h of initiating therapeutic hypothermia and at 5-6 days post therapeutic hypothermia. MATERIALS AND METHODS: Eleven neonates with HIE underwent MR spectroscopy of the basal ganglia and white matter. We compared metabolite concentrations during therapeutic hypothermia and post-therapeutic hypothermia and between moderate and severe HIE. RESULTS: During therapeutic hypothermia, neonates with severe HIE had decreased basal ganglia N-acetylaspartate (NAA; 0.62±0.08 vs. 0.72±0.05; P=0.02), NAA + N-acetylaspartylglutamate (NAAG; 0.66±0.11 vs. 0.77±0.06; P=0.05), glycerophosphorylcholine + phosphatidylcholine (GPC+PCh; 0.28±0.05 vs. 0.38±0.06; P=0.02) and decreased white matter GPC+PCh (0.35±0.13 vs. 0.48±0.04; P=0.02) compared to neonates with moderate HIE. For all subjects, basal gangliaNAA decreased (-0.08±0.07; P=0.01), whereas white matter GPC+PCh increased (0.03±0.04; P=0.04) from therapeutic hypothermia MRI to post-therapeutic-hypothermia MRI. All metabolite values are expressed in mmol/L. CONCLUSION: Decreased NAA and GPC+PCh were associated with greater HIE severity and could distinguish neonates who might benefit most from targeted additional neuroprotective therapies.
Entities:
Keywords:
Brain; Hypoxic–ischemic encephalopathy; Magnetic resonance imaging; Neonates; Spectroscopy
Authors: Steven P Miller; Nancy Newton; Donna M Ferriero; J Colin Partridge; David V Glidden; Alison Barnwell; Nathaniel A Chuang; Daniel B Vigneron; A James Barkovich Journal: Pediatr Res Date: 2002-07 Impact factor: 3.756
Authors: A J Barkovich; S P Miller; A Bartha; N Newton; S E G Hamrick; P Mukherjee; O A Glenn; D Xu; J C Partridge; D M Ferriero; D B Vigneron Journal: AJNR Am J Neuroradiol Date: 2006-03 Impact factor: 3.825
Authors: Denis V Azzopardi; Brenda Strohm; A David Edwards; Leigh Dyet; Henry L Halliday; Edmund Juszczak; Olga Kapellou; Malcolm Levene; Neil Marlow; Emma Porter; Marianne Thoresen; Andrew Whitelaw; Peter Brocklehurst Journal: N Engl J Med Date: 2009-10-01 Impact factor: 91.245
Authors: O Arteaga Cabeza; Z Zhang; E Smith Khoury; R A Sheldon; A Sharma; F Zhang; B S Slusher; R M Kannan; S Kannan; D M Ferriero Journal: Neurobiol Dis Date: 2020-11-30 Impact factor: 5.996
Authors: Rebekah Nixon; Ting Hin Richard Ip; Benjamin Jenkins; Ping K Yip; Paul Clarke; Vennila Ponnusamy; Adina T Michael-Titus; Albert Koulman; Divyen K Shah Journal: Nutrients Date: 2021-11-28 Impact factor: 5.717